Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[critical_perspective]

New Research on Anatabine recently published!

in the Journal of Inflammation 17 on August 24, 2020
Not sure if anyone posted this here before.

The study was targeting anatabine's effects on Inflammatory Bowel Diseases (IBD) such as Crohn's disease and ulcerative colitis (sound familiar?)

Conclusion: "These results suggest that anatabine administration might constitute a promising approach for the treatment of IBD." (p.11)

Very interesting to see that "All authors are employees of Philip Morris International"

So Philip Morris views anatabine as a worthwhile endeavor to pursue... but Jonnie has taken another route with Mymd??!! Why? Make your own conclusions...

You could read the entire article as an open access pdf below.
https://rdcu.be/cbi8v

Or here: https://doi.org/10.1186/s12950-020-00260-6